Bayhill files IPO papers, hunts for cash

At least one biotech is out to brave the chilly waters of Wall Street. Looking to gin some capital to cover the cost of upcoming clinical trials, Bayhill Therapeutics filed an IPO at least tentatively designed to raise about $86 million. Its experimental therapies are in studies to determine their effectiveness in restoring "tolerance" in immune systems, a new category of drugs with no currently approved therapies on the market. Bayhill has lost $13.5 million in the nine months through September 30, not unexpected in a company with no products on the market. Palo Alto, CA-based Bayhill's lead therapy is for multiple sclerosis with another program for type 1 diabetes.

- read the AP report

ALSO: Italy's Philogen says that regulators have OK'd its IPO. Report

Related Articles:
Bayhill raises $15.8M in VC. Report
M&A activity heats up as biotech IPOs struggle. Report
Biotech IPOs losing their attraction. Report
Deal-making hits a faster pace in '07. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.